Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-10-11 pm EDT			5-day change	1st Jan Change
84.95 ^USD	+0.33%		+0.43%	+4.86%

Oct. 11	Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79	MT
Oct. 09	Raymond James Adjusts Gilead Sciences Price Target to $95 From $94	MT

Evolution of the Average Target: Gilead Sciences, Inc.

average-target-price-chart GILEAD-SCIENCES-INC

Evolution of the Target Price: Gilead Sciences, Inc.

target-price-consensus-chart GILEAD-SCIENCES-INC

Changes in Analyst Recommendations: Gilead Sciences, Inc.

65e3fb5ae1af706aa2bdea.lfgvFKA0HaoL718qUuIWlnN1IgvhtGedEq084dN8ZP0.zZ9affEGTuI8gT1_C89H8DcmeE6E9QLqRu5dhp1PI7DDulhw6Fd80nrXOA~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79	Oct. 11	MT
Raymond James Adjusts Gilead Sciences Price Target to $95 From $94	Oct. 09	MT
JPMorgan Adjusts Price Target on Gilead Sciences to $100 From $95, Maintains Overweight Rating	Oct. 09	MT
Wells Fargo Upgrades Gilead Sciences to Overweight From Equalweight, Adjusts PT to $100 From $78	Oct. 07	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $74 From $71	Oct. 04	MT
Barclays Adjusts Price Target on Gilead Sciences to $84 From $76, Maintains Equalweight Rating	Oct. 04	MT
RBC Lifts Price Target on Gilead Sciences to $75 From $74, Keeps Sector Perform Rating	Oct. 04	MT
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $123 From $119, Maintains Buy Rating	Oct. 03	MT
Raymond James Raises Gilead Sciences' Price Target to $94 From $93, Outperform Rating Maintained	Sep. 11	MT
RBC Raises Price Target on Gilead Sciences to $74 From $72, Keeps Sector Perform Rating	Sep. 04	MT
Jefferies Adjusts Price Target on Gilead Sciences to $95 From $90, Maintains Buy Rating	Aug. 28	MT
Analyst recommendations: Cheniere, Gilead, Lowe's, Palo Alto, Starbucks...	Aug. 21
Truist Securities Adjusts Price Target on Gilead Sciences to $83 From $82, Maintains Hold Rating	Aug. 15	MT
Truist Adjusts Price Target on Gilead Sciences to $83 From $82, Maintains Hold Rating	Aug. 15	MT
Jefferies Adjusts Price Target on Gilead Sciences to $90 From $85, Maintains Buy Rating	Aug. 09	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $85 From $80, Maintains Outperform Rating	Aug. 09	MT
Morgan Stanley Raises Price Target on Gilead Sciences to $79 From $74, Keeps Equalweight Rating	Aug. 09	MT
RBC Raises Price Target on Gilead Sciences to $72 From $71, Keeps Sector Perform Rating	Aug. 09	MT
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75	Jul. 22	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating	Jul. 16	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78	Jul. 11	MT
RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating	Jul. 09	MT
Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93	Jul. 08	MT
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	Jun. 26	MT
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	Jun. 24	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	GILEAD SCIENCES, INC.					+0.48%
	ELI LILLY AND COMPANY					+7.16%
	NOVO NORDISK A/S					+15.28%
	JOHNSON & JOHNSON					+6.53%
	ABBVIE INC.					+2.58%
	MERCK & CO., INC.					+25.28%
	ROCHE HOLDING AG					+12.56%
	ASTRAZENECA PLC					+20.65%
	NOVARTIS AG					+1.63%
	AMGEN INC.					-0.85%
	Average					+9.13%
	Weighted average by Cap.					+9.73%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

84.95USD

Average target price

85.36USD

Spread / Average Target

+0.48%

High Price Target

123.00USD

Spread / Highest target

+44.79%

Low Price Target

68.50USD

Spread / Lowest Target

-19.36%

Analyst Consensus Detail

consensus-detail-chart GILEAD-SCIENCES-INC

Consensus revision (last 18 months)

consensus-revision-chart GILEAD-SCIENCES-INC

Analysts covering the company

Morgan Stanley
Raymond James
JPMorgan Chase
Wells Fargo Securities
Goldman Sachs
Barclays
RBC Capital Markets
Redburn Atlantic
UBS
Deutsche Bank Securities
Maxim
TD Cowen
Jefferies & Co.
HSBC
Argus
Cantor Fitzgerald
BMO Capital
Leerink Partners
Mizuho Securities
Truist Securities
Oppenheimer
Piper Sandler
BofA Securities
SVB Securities LLC
Cowen
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK	Elmar Kraus